单剂口服阿奇霉素联合或不联合阿莫西林预防喀麦隆高危分娩妇女围产期感染:随机对照试验
在喀麦隆开展的多中心、三组、双盲随机对照试验,纳入足月、非畸形、产程≥18小时或胎膜破裂≥8小时的临产妇女,比较单剂口服阿奇霉素(联合或不联合阿莫西林)与安慰剂预防围产期感染的效果。主要复合结局(母亲围产期感染或产后6周内任何原因死亡)在三组间无显著差异。
要点
- 单剂阿奇霉素联合或不联合阿莫西林未降低母亲围产期感染或死亡风险。
- 组2(阿奇霉素+阿莫西林)绒毛膜羊膜炎和伤口感染发生率显著低于安慰剂组。
- 新生儿感染及其他母儿结局在三组间无差异。
核心结论
- 对于足月产程延长或胎膜破裂的临产妇女,单剂口服阿奇霉素联合或不联合阿莫西林并未减少母亲围产期感染或新生儿感染。
研究设计与样本
- 多中心、三组、双盲随机对照试验,在喀麦隆进行,共随机756名妇女(组1 253例,组2 253例,组3 250例)。
- 纳入标准:足月、非畸形、活胎妊娠,产程≥18小时或胎膜破裂≥8小时。
- 排除标准:随机化前已患绒毛膜羊膜炎、研究药物禁忌或计划剖宫产。
主要发现
- 主要复合结局发生率:组1(阿奇霉素+安慰剂)6%,组2(阿奇霉素+阿莫西林)7%,组3(安慰剂)10%;组1 vs 组3 RR 0.6(95%CI 0.3-1.2),组2 vs 组3 RR 0.7(95%CI 0.4-1.3)。
- 绒毛膜羊膜炎发生率组2为3.2%,组3为0.4%(P=0.02);伤口感染组2为4%,组3为0.8%(P=0.02)。
- 其他母亲或新生儿结局(包括新生儿感染)在三组间无差异。
关键数值与推荐
- 主要结局为母亲围产期感染或产后6周内任何原因死亡的复合结局。
- 每组预计241例(总750例)以80%把握度、双侧α=0.05(每次比较0.025)检测50%效应量,假设基线复合感染率20%。
临床怎么用
- 对于足月产程延长或胎膜破裂的临产妇女,不推荐常规给予单剂口服阿奇霉素(联合或不联合阿莫西林)以预防围产期感染。
- 研究中常规抗生素使用率较高(各组超过60%接受青霉素等),可能影响结果外推。
局限性
- 实际感染率低于预期(安慰剂组10% vs 假设20%),可能降低统计效能。
- 各组常规抗生素使用频繁(超过60%),可能掩盖干预效果。
- 研究对象为喀麦隆特定人群,外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the effectiveness of single-dose azithromycin, with or without amoxicillin, with placebo to prevent peripartum infection in laboring women. METHODS: We conducted a multicenter, three-group, double-blind randomized controlled trial of women with viable term nonanomalous pregnancies with either prolonged labor of 18 hours or longer or rupture of membranes for 8 hours or longer in Cameroon. Women with chorioamnionitis before randomization, study drug contraindications, or planned cesarean births were excluded. Women were randomized to oral azithromycin 1 g-placebo (group 1), oral azithromycin 1 g-oral amoxicillin 2 g (group 2), or placebo-placebo (group 3). All groups received usual care, including antibiotics given at the health care professional's discretion. The primary outcome was a composite of maternal peripartum infection or death from any cause up to 6 weeks postpartum. Two primary comparisons (group 1 vs group 3 and group 2 vs group 3) were planned. We estimated that 241 women per group (planning for 750 total) would provide 80% power at two-sided α=0.05 (0.025 per comparison) to detect a 50% effect size assuming 20% baseline composite infection rate. RESULTS: From January 6, 2018, to May 15, 2020, 6,531 women were screened, and 756 (253 in group 1, 253 in group 2, and 250 in group 3) were randomized. Baseline characteristics (including body mass index, duration of rupture of membranes or labor, and parity) were balanced across groups, except for maternal age. More than 60% of women in each group received usual-care antibiotics: more than 90% penicillin and approximately 50% for prolonged rupture of membranes across all study groups. Composite outcome incidences were similar in antibiotic groups 1 (6%) and 2 (7%) compared with placebo group 3 (10%) (RR 0.6, 95% CI 0.3-1.2; 0.7, 95% CI 0.4-1.3, respectively). Chorioamnionitis and wound infection were significantly lower in group 2 (3.2% vs 0.4% and 4% vs 0.8% respectively, both P=.02) compared with group 3. There were no differences in other maternal or neonatal outcomes including neonatal infection. CONCLUSION: A single dose of oral azithromycin with or without amoxicillin for prolonged labor or rupture of membranes at term did not reduce maternal peripartum or neonatal infection. Observed lower than expected infection rates and frequent usual-care antibiotic use may have contributed to these findings. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT03248297. FUNDING SOURCE: Merck for Mothers Investigator Studies Program grant.
引用
- Subramaniam A, Ye Y, Mbah R, et al. Single Dose of Oral Azithromycin With or Without Amoxicillin to Prevent Peripartum Infection in Laboring, High-Risk Women in Cameroon: A Randomized Controlled Trial. Obstet Gynecol. 2021. PMID: 34619734. doi:10.1097/AOG.0000000000004565
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。